• https://fast.wistia.net/embed/iframe/oe24g55seg?autoPlay=true
    play

  • Our immunoblot test detects seroconversion earlier than other confirmation technologies and gives less indeterminate results5-6. This reduces the need for repeated testing and thus limiting extra costs.

    Compared to other testing technologies the INNO-LIA HIV I/II Score assay provides clear differentiation of HIV-1 and HIV-2 infections6-7-8 - which allows for much more adequate patient treatment.

  • These are some of the key advantages of using our gold standard immunoblot assay for HIV confirmation testing:

    • It’s the latest generation of a reference test with more than 25 years of accumulated and widely documented HIV testing results across the world.
    • It reliably confirms and differentiates HIV-1, HIV-1 group O, and HIV-2.
    • It gives a low number of indeterminate results.
    • It comes with ready-to-use and color coded reagents.
    • It offers clear cut, standardized and objective reading and interpretation of results.
    • It features flexible strip processing with both short and overnight procedures plus efficient walk-away automation; read the results when you are ready.

    Download our leaflet below for full background information about the characteristics and references of the INNO-LIA Score product range, or click here to go to the INNO-LIA HIV I/II Score product page.

  • References:

    1. CDC Updated Recommendations for Laboratory Testing for the Diagnosis of HIV infection (published June 27, 2014)
    2. Public Health England – UK Standards for Microbiology Investigations / HIV screening and confirmation (Issue date 03.01.17)
    3. WHO guidelines – Screening donated blood for Transfusion-Transmissible Infections & Consolidated guidelines on HIV testing Services (July 2015)
    4. European guidelines: Guide to the preparation, use and quality assurance of blood components.  Recommendation No.R(95) 15
    5. Comparison studies performed at Fujirebio Europe N.V. using BBI seroconversion and low-titer panels.
    6. WHO report 16 "HIV ASSAYS: OPERATIONAL CHARACTERISTICS" – 2009
    7. Test performance data – IFU INNO-LIA™ HIV I/II Score assay
    8. Hønge BL et al. HIV Medicine (2018). The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections.